ReviewJournal of clinical medicine2026
Preventing Post-ERCP Pancreatitis: A Pragmatic Clinical Pathway from Periprocedural Prophylaxis to Early Postprocedural Triage.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) remains the most frequent and clinically relevant adverse event after ERCP. Although several preventive measures are supported by current evidence, their application in routine practice is often fragmented across the pre-procedural, intra-procedural, and post-procedural phases of care. As a result, patients with evolving risk may not receive timely escalation of prophylaxis or appropriately tailored post-procedural monitoring. This review provides a pragmatic clinical framework for integrating evidence-based PEP prevention with early post-ERCP risk stratification. We summarize baseline risk assessment before ERCP, distinguish routinely applicable preventive measures from strategies reserved for selected high-risk situations, and emphasize the importance of intra-procedural reassessment when procedural events such as difficult cannulation or unintended pancreatic duct manipulation increase risk in real time. We further discuss the role of early symptom assessment and post-procedural amylase/lipase measurement in supporting triage decisions, including selective observation, admission, or same-day discharge in appropriately selected patients. This integrated approach may improve consistency in routine ERCP care while highlighting important limitations related to generalizability, local resources, and implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.